Literature DB >> 29443413

Vascular access for therapeutic plasma exchange.

Tina S Ipe1, Marisa B Marques2.   

Abstract

Therapeutic plasma exchange is an apheresis modality in which plasma is separated from the blood cellular components ex vivo, discarded, and replaced with an isosmotic fluid (most commonly 5% albumin) to maintain appropriate oncotic pressure in the patient. Therapeutic plasma exchange is used in the treatment of many diseases and indications. The recent seventh edition of the American Society for Apheresis guidelines indicates approximately 72 diseases and 116 indications for which therapeutic plasma exchange may be effective. One of the critical aspects for the successful performance of therapeutic plasma exchange is appropriate vascular access to provide high blood flow for the collection and return phases of the procedure, especially because most patients who need therapeutic plasma exchange will require more than one treatment over days to weeks. This article provides an overview of the characteristics of therapeutic plasma exchange, the clinical diseases and indications that may be treated with therapeutic plasma exchange, and the different types of vascular access employed, with their advantages and disadvantages. The latter may include peripheral venous access and intravascular or implantable access devices, such as arteriovenous grafts and fistulas, central venous catheters, and central venous catheters tunneled with ports.
© 2018 AABB.

Entities:  

Mesh:

Year:  2018        PMID: 29443413     DOI: 10.1111/trf.14479

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

Review 1.  An update on lipid apheresis for familial hypercholesterolemia.

Authors:  Christina Taylan; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2022-04-25       Impact factor: 3.651

2.  Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS).

Authors:  Seyed MohammadReza Hashemian; Navid Shafigh; Golnaz Afzal; Hamidreza Jamaati; Payam Tabarsi; Majid Marjani; Majid Malekmohammad; Seyed Mehdi Mortazavi; Batoul Khoundabi; Davood Mansouri; Afshin Moniri; Abbas Hajifathali; Elham Roshandel; Esmaeil Mortaz; Ian M Adcock
Journal:  Pulmonology       Date:  2020-12-04

Review 3.  Plasma exchange in the intensive care unit: a narrative review.

Authors:  Philippe R Bauer; Marlies Ostermann; Lene Russell; Chiara Robba; Sascha David; Bruno L Ferreyro; Joan Cid; Pedro Castro; Nicole P Juffermans; Luca Montini; Tasneem Pirani; Andry Van De Louw; Nathan Nielsen; Julia Wendon; Anne C Brignier; Miet Schetz; Jan T Kielstein; Jeffrey L Winters; Elie Azoulay
Journal:  Intensive Care Med       Date:  2022-08-12       Impact factor: 41.787

4.  Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.

Authors:  L J Blumberg; J E Humphries; S D Jones; L B Pearce; R Holgate; A Hearn; J Cheung; A Mahmood; B Del Tito; J S Graydon; L E Stolz; A Bitonti; S Purohit; D de Graaf; K Kacena; J T Andersen; G J Christianson; D C Roopenian; J J Hubbard; A K Gandhi; K Lasseter; M Pyzik; R S Blumberg
Journal:  Sci Adv       Date:  2019-12-18       Impact factor: 14.136

Review 5.  In Translation: FcRn across the Therapeutic Spectrum.

Authors:  Timothy Qi; Yanguang Cao
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

Review 6.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

7.  Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia.

Authors:  Julia Lischka; Klaus Arbeiter; Charlotte de Gier; Andrea Willfort-Ehringer; Nina-Katharina Walleczek; Renata Gellai; Michael Boehm; Albert Wiegman; Susanne Greber-Platzer
Journal:  BMC Pediatr       Date:  2022-03-12       Impact factor: 2.567

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.